The RATIONALE-306 study, a global trial involving both East Asian and Western...
How does the NEMIO trial improve neoadjuvant chemotherapy in the perioperative...
The TROPION-Breast01 study enrolled over 700 HR+/HER2- breast cancer patients...
The CodeBreak 300 is the first phase 3 trial including chemorefractory patients...
Since RET fusions are a rare subgroup, comprising less than 5% of NSCLC...
The widely recognized enfortumab vedotin (EV), which targets nectin-4, was...
Episode 19: Efficacy of ADC therapy in HER2 low breast cancer: updated results from DESTINY-Breast04
While ADCs have shown efficacy in HER2+ disease, this trial focuses on HER2-low...
Depending on the molecular profile of the tumour different treatment options...
Chemotherapy combined with immunotherapy yields superior results compared to...
In metastatic renal cell cancer (mRCC), immune checkpoint inhibitors (ICI) are...